<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03368547</url>
  </required_header>
  <id_info>
    <org_study_id>16-001684</org_study_id>
    <secondary_id>NCI-2016-01768</secondary_id>
    <nct_id>NCT03368547</nct_id>
  </id_info>
  <brief_title>68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery</brief_title>
  <official_title>68Ga-PSMA-11 PET/CT for Staging of Intermediate and High Risk Prostate Cancer Prior to Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies how well 68Ga-PSMA-11 positron emission tomography (PET)/computed&#xD;
      tomography (CT) works in imaging patients with intermediate or high risk prostate cancer&#xD;
      before surgery. Diagnostic procedures, such as PET/CT scans, may help find and diagnose&#xD;
      prostate cancer and find out how far the disease has spread.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To assess the sensitivity and specificity of gallium Ga 68 gozetotide (68Ga-PSMA-11) PET&#xD;
      for the detection of regional nodal metastases compared to pathology at radical prostatectomy&#xD;
      on a per patient basis, and on a per patient basis using nodal regional correlation.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the positive and negative predictive value of 68Ga-PSMA-11 PET for the detection&#xD;
      of regional nodal metastases compared to pathology at radical prostatectomy on a per patient&#xD;
      basis, and on a per patient basis using nodal regional correlation.&#xD;
&#xD;
      II. To assess sensitivity, specificity, positive and negative predictive value of 68Ga-&#xD;
      PSMA-11 PET for the detection of extra-pelvic nodal metastases, visceral metastases and&#xD;
      osseous metastases compared to biopsy and imaging follow-up.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive 68Ga-PSMA-11 intravenously (IV) and undergo PET/CT scan over 20-50 minutes&#xD;
      on day 1.&#xD;
&#xD;
      After completion of study, patients are followed up at 2-4 days, then at 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2016</start_date>
  <completion_date type="Actual">June 18, 2021</completion_date>
  <primary_completion_date type="Actual">June 18, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of 68Ga-PSMA-11 positron emission tomography for the detection of regional nodal metastases compared to pathology at radical prostatectomy on a per patient basis and using nodal regional correlation</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of 68Ga-PSMA-11 positron emission tomography for the detection of regional nodal metastases compared to pathology at radical prostatectomy on a per patient basis and using nodal regional correlation</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive predictive value of 68Ga-PSMA-11 positron emission tomography for the detection of regional nodal metastases compared to pathology at radical prostatectomy on a per patient basis and using nodal regional correlation</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Negative predictive value of 68Ga-PSMA-11 positron emission tomography for the detection of regional nodal metastases compared to pathology at radical prostatectomy on a per patient basis and using nodal regional correlation</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of 68Ga-PSMA-11 positron emission tomography for the detection of extra-pelvic nodal metastases, visceral metastases, and osseous metastases compared to biopsy and imaging follow-up</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity of 68Ga-PSMA-11 positron emission tomography for the detection of extra-pelvic nodal metastases, visceral metastases, and osseous metastases compared to biopsy and imaging follow-up</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value of 68Ga-PSMA-11 positron emission tomography for the detection of extra-pelvic nodal metastases, visceral metastases, and osseous metastases compared to biopsy and imaging follow-up</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value of 68Ga-PSMA-11 positron emission tomography for the detection of extra-pelvic nodal metastases, visceral metastases, and osseous metastases compared to biopsy and imaging follow-up</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Sensitivity for detection of regional nodal metastases in comparison to cross sectional imaging performed contemporaneously with the 68Ga-PSMA-11 positron emission tomography</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </other_outcome>
  <other_outcome>
    <measure>Specificity for detection of regional nodal metastases in comparison to cross sectional imaging performed contemporaneously with the 68Ga-PSMA-11 positron emission tomography</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </other_outcome>
  <other_outcome>
    <measure>Positive predictive value for detection of regional nodal metastases in comparison to cross sectional imaging performed contemporaneously with the 68Ga-PSMA-11 positron emission tomography</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </other_outcome>
  <other_outcome>
    <measure>Negative predictive value for detection of regional nodal metastases in comparison to cross sectional imaging performed contemporaneously with the 68Ga-PSMA-11 positron emission tomography</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be summarized by descriptive statistics.</description>
  </other_outcome>
  <other_outcome>
    <measure>PSA progression free survival</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Will compare patients with and without pelvic nodal metastases.</description>
  </other_outcome>
  <other_outcome>
    <measure>Standardized uptake value maximum and short axis diameter of nodal disease on cross sectional imaging correlated to presence of true pathology</measure>
    <time_frame>Up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of osseous and distant metastatic lesions</measure>
    <time_frame>Up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Impact of 68Ga-PSMA-11 positron emission tomography on clinical management</measure>
    <time_frame>Up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>Assessed per Common Terminology Criteria for Adverse Events version 4.03.</description>
  </other_outcome>
  <other_outcome>
    <measure>Inter-reader reproducibility</measure>
    <time_frame>Up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Sensitivity and specificity on lesions level for 68Ga-PSMA-11 positron emission tomography and multiparametric magnetic resonance imaging</measure>
    <time_frame>Up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quantitative parameters for malignant and benign lesions (BPH, hgPIN, inflammation) in 68Ga-PSMA-11 positron emission tomography and multiparametric magnetic resonance imaging</measure>
    <time_frame>Up to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Gross-tumor-volume using 68Ga-PSMA-11 positron emission tomography and multiparametric magnetic resonance imaging</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be compared to tumor extent in histopathology.</description>
  </other_outcome>
  <other_outcome>
    <measure>Lesional standardized uptake value maximum from 68Ga-PSMA-11</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Will be correlated with immunohistochemical stainings (e.g. PSMA, PI3K, Akt) and Gleason score.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1138</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>Stage IIB Prostate Cancer AJCC v7</condition>
  <condition>Stage III Prostate Cancer AJCC v7</condition>
  <condition>Stage IV Prostate Cancer AJCC v7</condition>
  <arm_group>
    <arm_group_label>Diagnostic (68Ga-PSMA-11, PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 68Ga-PSMA-11 IV and undergo PET/CT scan over 20-50 minutes on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo PET/CT scan</description>
    <arm_group_label>Diagnostic (68Ga-PSMA-11, PET/CT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT Scan</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Gallium Ga 68 Gozetotide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (68Ga-PSMA-11, PET/CT)</arm_group_label>
    <other_name>(68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68Ga)Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-DKFZ-PSMA-11</other_name>
    <other_name>68Ga-HBED-CC-PSMA</other_name>
    <other_name>68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-PSMA</other_name>
    <other_name>68Ga-PSMA-11</other_name>
    <other_name>68Ga-PSMA-HBED-CC</other_name>
    <other_name>[68Ga] Prostate-specific Membrane Antigen 11</other_name>
    <other_name>[68Ga]GaPSMA-11</other_name>
    <other_name>Ga PSMA</other_name>
    <other_name>Ga-68 labeled DKFZ-PSMA-11</other_name>
    <other_name>Ga-68 labeled PSMA-11</other_name>
    <other_name>Gallium Ga 68 PSMA-11</other_name>
    <other_name>Gallium Ga 68-labeled PSMA-11</other_name>
    <other_name>GALLIUM GA-68 GOZETOTIDE</other_name>
    <other_name>Gallium-68 PSMA</other_name>
    <other_name>Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>GaPSMA</other_name>
    <other_name>PSMA-HBED-CC GA-68</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/CT scan</description>
    <arm_group_label>Diagnostic (68Ga-PSMA-11, PET/CT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy proven prostate adenocarcinoma&#xD;
&#xD;
          -  Considered for prostatectomy with lymph node dissection&#xD;
&#xD;
          -  Intermediate to high-risk disease (as determined by elevated prostate specific antigen&#xD;
             [PSA] [PSA &gt; 10], tumor [T]-stage [T2b or greater], Gleason score [Gleason score &gt; 6]&#xD;
             or other risk factors)&#xD;
&#xD;
          -  Able to provide written consent&#xD;
&#xD;
          -  Karnofsky performance status of &gt;= 50 (or Eastern Cooperative Oncology Group&#xD;
             [ECOG]/World Health Organization [WHO] equivalent)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients not capable of getting PET study due to weight, claustrophobia, or inability&#xD;
             to lay still for the duration of the exam&#xD;
&#xD;
          -  Neoadjuvant chemotherapy or radiation therapy prior to prostatectomy including focal&#xD;
             ablation techniques (high-intensity focused ultrasound ablation [HiFu])&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Czernin</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 27, 2017</study_first_submitted>
  <study_first_submitted_qc>December 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2017</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
    <mesh_term>Gallium 68 PSMA-11</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

